^
Association details:
Biomarker:ATM mutation
Cancer:Prostate Cancer
Drug:Bavencio (avelumab) (PD-L1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

631P - Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study

Published date:
09/13/2021
Excerpt:
These 2 responders had both a known HRD deleterious mutation (one BRCA2, one ATM). Disease control rate was 69.2% (18/26). Median radiographic PFS was 6.78 months (95% CI 4.28-9.01) and median OS 10.56 months (95% CI 6.68-NR)...Avelumab plus carboplatin has an acceptable safety profile. Overall clinical benefit was seen in almost 70% of patients and was associated with a prolonged OS given the heavily pretreated population.
Secondary therapy:
carboplatin
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study

Published date:
10/26/2022
Excerpt:
Safety and efficacy avelumab plus carboplatin was investigated in a single-arm Phase Ib study in mCRPC...Two of these responders had a known DDR alteration (one BRCA2, one ATM).
DOI:
https://doi.org/10.1038/s41416-022-01991-4